Zobrazeno 1 - 10
of 157
pro vyhledávání: '"erythropoietin‐stimulating agent"'
Publikováno v:
Open Medicine, Vol 19, Iss 1, Pp 529-42 (2024)
The management of patients undergoing bilateral nephrectomy for renal cancer presents significant challenges, particularly in addressing hypotension, anemia, and tumor recurrence during hemodialysis.
Externí odkaz:
https://doaj.org/article/67c21466754f4f20a0bb759b33d2dbe8
Publikováno v:
BMC Nephrology, Vol 24, Iss 1, Pp 1-9 (2023)
Abstract Background Patients with chronic kidney disease (CKD) present high mortality and morbidity rates despite the availability of various therapies. Although CKD-mineral and bone disorder (MBD) and renal anemia are important factors in patients w
Externí odkaz:
https://doaj.org/article/529c623a4e6945df91a6907977e5fab5
Publikováno v:
BMC Nephrology, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background Appropriate management of anemia in patients with hemodialysis (HD) involves the administration of iron supplementation and erythropoietin-stimulating agents (ESAs), in addition to monitoring the response. This study aimed to eval
Externí odkaz:
https://doaj.org/article/089341da50a24cd2b2102d698041875f
Autor:
Henry H.L. Wu, Rajkumar Chinnadurai
Publikováno v:
Kidney Diseases, Pp 1-12 (2022)
Background: Erythropoietin-stimulating agent (ESA) hyporesponsiveness is commonly observed in patients with anemia secondary to chronic kidney disease (CKD). Because of its complexity, a global consensus on how we should define ESA hyporesponsiveness
Externí odkaz:
https://doaj.org/article/1af93dfbd3c545e6bb5cc2be707c0088
Autor:
Yuki Kawai, Yoshiyuki Toya, Hiromichi Wakui, Tetsuya Fujikawa, Eiko Ueda, Kengo Azushima, Sho Kinguchi, Hiroshi Mitsuhashi, Tomoyuki Kawano, Tadashi Kuji, Satoshi Yamaguchi, Toshimasa Ohnishi, Kouichi Tamura
Publikováno v:
Journal of Pharmacological Sciences, Vol 147, Iss 1, Pp 118-125 (2021)
Our previous randomized controlled trial comparing the total dose of weekly versus biweekly continuous erythropoietin receptor activator (CERA) therapy to maintain optimal hemoglobin (Hb) levels showed no significant differences between the two thera
Externí odkaz:
https://doaj.org/article/bc8b5ab08cbb441db2084058f0dfc4de
Autor:
Yuki Kawai, Yoshiyuki Toya, Hiromichi Wakui, Tetsuya Fujikawa, Eiko Ueda, Kengo Azushima, Hiroshi Mitsuhashi, Tomoyuki Kawano, Tadashi Kuji, Satoshi Yamaguchi, Toshimasa Ohnishi, Kouichi Tamura
Publikováno v:
The Journal of Clinical Hypertension, Vol 23, Iss 4, Pp 870-878 (2021)
Abstract Although continuous erythropoietin receptor activators (CERAs) are widely used erythropoiesis‐stimulating agents for correcting renal anemia in patients undergoing hemodialysis (HD), few reports have examined weekly CERA administration. In
Externí odkaz:
https://doaj.org/article/62f0e25c3ca842bebc112335d5734937
Autor:
Kohji Ohki, Hiromichi Wakui, Kazushi Uneda, Kengo Azushima, Kotaro Haruhara, Sho Kinguchi, Shingo Urate, Takayuki Yamada, Takahiro Yamaji, Ryu Kobayashi, Tomohiko Kanaoka, Shintaro Minegishi, Tomoaki Ishigami, Tetsuya Fujikawa, Yoshiyuki Toya, Kouichi Tamura
Publikováno v:
Kidney Diseases, Vol 6, Iss 4, Pp 299-308 (2020)
Introduction: Erythropoietin-stimulating agents (ESAs) are used to treat renal anemia in patients with non-dialysis CKD, but this can lead to increases in blood pressure (BP). Objective: We investigated the effects of continuous erythropoietin recept
Externí odkaz:
https://doaj.org/article/5cabaa8899da467ca1696452109a817c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.